All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-11-24T09:30:37.000Z

Towards ASH 2020: Highlights on smoldering multiple myeloma

Bookmark this article

Since the last American Society of Hematology (ASH) meeting, smoldering multiple myeloma (SMM) has continued to draw attention in the field of multiple myeloma (MM). Recent discussions focused on two main topics: identifying the patients who could benefit the most from early treatment and how they should be treated.

To prepare for the 62nd ASH Annual Meeting & Exposition, which will be held between December 5–8, 2020, we have summarized the recent advances in SMM covered on the Multiple Myeloma Hub from last year, and how we plan to cover this topic at the 2020 meeting.

How to accurately identify candidates for early intervention

We were pleased to speak to the Multiple Myeloma Hub Steering Committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, about the recent advances in our understanding of myeloma progression during the 6th Controversies in Multiple Myeloma (COMy) World Congress. Irene Ghobrial discussed the need for criteria to define patients who would progress to active MM in their lifetime and benefit from early intervention. Listen below to her detailed explanation of the clinical markers to help experts define patients with high-risk SMM.

Recent advances in our understanding of myeloma progression

In 2019, the International Myeloma Working Group (IMWG) revised its diagnostic criteria for high-risk SMM as a “2/20/20” model, which corresponds to:

  • Serum M protein > 2 g/dL
  • Involved to uninvolved serum free light-chain ratio > 20
  • Bone marrow plasma cell infiltration > 20%

This risk stratification model is considered a useful tool in identifying patients with SMM who have a > 50% probability of progressing to MM in 2 years. The presence of a chromosomal abnormality may be included as an additional risk factor to these three parameters. A more detailed discussion on the IMWG 2/20/20 risk stratification model can be found here.

During the 2020 ASH meeting, we will learn about several initiatives attempting to identify more accurately patients who are at a higher risk of progression to MM amongst those who could be safely followed with a ‘watch and wait’ approach. Upcoming abstracts include:

  • The iMMunocell study by Rosalinda Termini, investigating longitudinal immunogenomic profiling of tumor and immune cells
  • A comprehensive genomic analysis that could help in identifying low-risk SMM, by Anil Aktas-Samur
  • The use of low-dose whole-body CT to detect bone lesions at an early stage in progression to MM, by Maria Gavriatopoulou
  • The impact of CD56 expression on disease progression by Laura Notarfranchi
  • The results of a prospective observational study investigating a variety of genomic, immunological, and clinical parameters that may be predictors of progression, by Elisabet Manasanch

How to treat SMM

The debate on whether SMM should be treated early, when it is a less complex disease, is still ongoing.

Watch our interview from the 61st ASH meeting with Irene Ghobrial on treating SMM. Irene Ghobrial argues that patients with SMM should be treated once there is an agreement on defined selection criteria, and she discusses SMM therapeutic options such as lenalidomide-based therapies and daratumumab for low-risk SMM.

How should we treat smoldering myeloma?

In the following interview from ASH 2019, Mark Bustoros, Dana-Farber Cancer Institute, Boston, US, presents the results from a phase II trial of ixazomib, lenalidomide, and dexamethasone in treating high-risk SMM. This combination is associated with promising results with a favorable safety profile.

What are the latest advances in treating high-risk smoldering myeloma?

During the eighth annual meeting of the Society of Hematologic Oncology (SOHO), Angela Dispenzieri, Mayo Clinic, Rochester, US, and Multiple Myeloma Hub Co-Chair, María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, debated whether SMM should be treated. María-Victoria Mateos has argued that patients should be treated from two main perspectives: (1) to prevent the development of MM, and (2) to cure the disease before progression to MM. Several agents, including elotuzumab, ixazomib, carfilzomib, isatuximab, and daratumumab, demonstrated positive results for prevention. In a curative approach, carfilzomib-based therapies were associated with promising results based on the phase II GEM-CESAR trial data. On the other hand, Angela Dispenzieri argued that SMM should not be treated yet, as most cases identified by the available tools today would not progress to MM. She advocates for a larger and broader validation of the described SMM risk stratification models. Find out more on this thorough discussion here.

At the moment, there are several ongoing clinical trials, but the GEM-CESAR study presented last year at ASH leads the field of curative approaches being evaluated for patients with SMM. Review the preliminary key results in this interview with María-Victoria Mateos:

Has the GEM-CESAR study demonstrated that early intervention in SMM should be a new SOC?

New treatment approaches for high-risk SMM will be also be discussed this year. Dickran Kazandjian and Elizabeth Hill, of the National Cancer Institute, Bethesda, US, will be presenting the results of a phase II study evaluating carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance and the value of 18f-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) for the evaluation of the depth of response achieved with it. Additionally, Shaji Kumar will present preliminary safety data from phase II ASCENT trial investigating induction (carfilzomib, lenalidomide, daratumumab, dexamethasone), consolidation (daratumumab, dexamethasone), and maintenance (lenalidomide, daratumumab) approaches in patients with high-risk SMM.

The MM Hub will be providing live coverage, summary articles on key sessions, and interviews with leaders in the myeloma field during the 62nd ASH Annual Meeting & Exposition. Stay tuned!

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox